| Deal value | $50M |
|---|---|
| Share of market cap | 20.8% |
Key highlights
- $50.0 million gross proceeds through the sale of 2,466,395 common shares
- Offer price of $20.27 per share represents an 80% premium to the 30-day average
- Agreement includes a 365-day lock-up period and a 24-month standstill provision
- Potential $11.1 million refund required if a definitive license is not signed by May 2027
- Strategic alignment includes an MOU for Japanese pandemic preparedness and response
What Is the Capital Raise?
Arcturus Therapeutics (NASDAQ: ARCT) has finalized a $50.0 million equity financing through a private placement with Meiji Seika Pharma. The transaction involved the sale of 2,466,395 shares of common stock at a purchase price of $20.27 per share. This pricing reflects a substantial 80% premium over the 30-day average closing price through November 11, 2026. The agreement contains a unique clawback provision: if the companies do not execute a definitive license agreement by May 31, 2027, Arcturus must refund approximately $11.1 million of the premium to Meiji in either cash or common stock. Meiji is now subject to a one-year lock-up and a 9.9% ownership cap.
Use of Proceeds
- Accelerate clinical development of ARCT-2601 for the treatment of OTC deficiency
- Validate the next-generation LUNAR 2.0 messenger RNA delivery platform
- Advance the company's existing cystic fibrosis respiratory program
- Support manufacturing expertise and drug substance development for the mRNA pipeline
- Provide working capital for the expanded Japanese collaboration and pandemic preparedness
Strategic Rationale
The investment cements a deepening partnership between Arcturus and Meiji, moving beyond their existing vaccine commercialization work. By securing capital at a significant premium to its current market valuation, Arcturus strengthens its balance sheet while minimizing shareholder dilution. The deal is part of a broader strategic framework that includes a license for self-amplifying mRNA technology and a Memorandum of Understanding for pandemic response in Japan. This collaboration leverages Arcturus' STARR technology to address undisclosed therapeutic areas, positioning the company as a key infrastructure partner for Japan's domestic healthcare security.
Business Overview
Based in San Diego, Arcturus Therapeutics is a clinical-stage biotechnology firm specializing in messenger RNA medicines for rare liver diseases and respiratory conditions. The company's platform is built on three pillars: LUNAR lipid-mediated delivery, STARR self-amplifying mRNA technology, and specialized manufacturing capabilities. Arcturus developed KOSTAIVE, the first self-amplifying mRNA COVID-19 vaccine to receive global approval. Its current pipeline includes high-priority programs for cystic fibrosis, ornithine transcarbamylase deficiency, and phenylketonuria, supported by a portfolio of over 500 patents and applications across major global markets.
Financial Context
- Annual revenue reported at $67.22 million with quarterly revenue of $16.85 million
- Current market cap stands at $240.96 million following a period of high volatility
- Relative Strength Index of 37.0 suggests the stock is trading near technical support levels
- Stock price recently closed at $8.36, significantly below the $20.27 Meiji entry price
Down 0.6% since our story on 16 Nov: $8.36 when we broke it → $8.31 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $10.42 |
|---|---|
| 20 Oct | $10.98 |
| 21 Oct | $11.07 |
| 22 Oct | $10.73 |
| 23 Oct | $9.84 |
| 26 Oct | $9.91 |
| 27 Oct | $11.23 |
| 28 Oct | $12.07 |
| 29 Oct | $12.15 |
| 30 Oct | $11.03 |
| 2 Nov | $9.49 |
| 3 Nov | $9.54 |
| 4 Nov | $10.87 |
| 5 Nov | $9.36 |
| 6 Nov | $10.35 |
| 9 Nov | $9.49 |
| 10 Nov | $9.39 |
| 11 Nov | $9.31 |
| 12 Nov | $8.44 |
| 13 Nov | $8.36 |
| 16 Nov | $8.31 |
Management commentary
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
| Share price | $8.36 |
|---|---|
| Market cap | $241M |
| Revenue (annual) | $67M |
| 1-month price change | -24.82% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Arcturus Therapeutics Holdings Inc. announcing a $50 million securities purchase agreement with Meiji Seika Pharma.
Track Arcturus Therapeutics Holdings Inc. live
Get the next Arcturus Therapeutics Holdings Inc. SEC filing seconds after it lands.



